Methods of treating cancer
The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.
1. A method of treating a disease which is chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in a patient in need of treatment with ponatinib, wherein the patient is treated with a strong CYP3A4 inhibitor, comprising:
(a) stopping the strong CYP3A4 inhibitor treatment;
(b) delaying administering, for at least 3 days after stopping the strong CYP3A4 inhibitor treatment, a dose of ponatinib that the patient would have received based on the patient's age and condition if the patient had not been treated with the strong CYP3A4 inhibitor; and then
(c) administering the dose of ponatinib that the patient would have received based on the patient's age and condition if the patient had not been treated with the strong CYP3A4 inhibitor;
wherein the strong CYP3A4 inhibitor is posaconazole.
2. The method of claim 1 , wherein the delaying in step (b) is at least 4 days.
3. The method of claim 1 , wherein the delaying in step (b) is at least 5 days.
4. The method of claim 1 , wherein the delaying in step (b) is at least 6 days.
5. The method of claim 1 , wherein the delaying in step (b) is at least 7 days.
6. The method of claim 1 , wherein the delaying in step (b) is at least 8 days.
7. The method of claim 1 , wherein the delaying in step (b) is in the range of from 3-11 days.
8. The method of claim 1 , wherein the delaying in step (b) is in the range of from 3-9 days.
9. The method of claim 1 , wherein the delaying in step (b) is in the range of from 3-7 days.
10. The method of claim 1 , wherein the delaying in step (b) is in the range of from 3-6 days.
11. The method of claim 1 , wherein the delaying in step (b) is in the range of from 3-5 days.
12. The method of claim 1 , wherein the disease is CML.
13. The method of claim 12 , wherein the CML is chronic phase (CP) CML.
14. The method of claim 12 , wherein the CML is accelerated phase (AP) CML.
15. The method of claim 12 , wherein the CML is blast phase (BP) CML.
16. The method of claim 12 , wherein the CML is T315I-positive CML.
17. The method of claim 16 , wherein the T315I-positive CML is CP T315I-positive CML.
18. The method of claim 16 , wherein the T315I-positive CML is AP T315I-positive CML.
19. The method of claim 16 , wherein the T315I-positive CML is BP T315I-positive CML.
20. The method of claim 1 , wherein the disease is Ph+ ALL.
21. The method of claim 20 , wherein the Ph+ALL is T315I-positive Ph+ALL.
22. The method of claim 12 , wherein the delaying in step (b) is in the range of from 3-7 days.
23. The method of claim 13 , wherein the delaying in step (b) is in the range of from 3-7 days.
24. The method of claim 14 , wherein the delaying in step (b) is in the range of from 3-7 days.
25. The method of claim 15 , wherein the delaying in step (b) is in the range of from 3-7 days.
26. The method of claim 16 , wherein the delaying in step (b) is in the range of from 3-7 days.
27. The method of claim 17 , wherein the delaying in step (b) is in the range of from 3-7 days.
28. The method of claim 18 , wherein the delaying in step (b) is in the range of from 3-7 days.
29. The method of claim 19 , wherein the delaying in step (b) is in the range of from 3-7 days.
30. The method of claim 20 , wherein the delaying in step (b) is in the range of from 3-7 days.
31. The method of claim 21 , wherein the delaying in step (b) is in the range of from 3-7 days.
32. The method of claim 1 , wherein ponatinib is ponatinib hydrochloride.